Meropenem/vaborbactam
Combination antibiotic drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Meropenem/vaborbactam?
Summarize this article for a 10 year old
Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia.[1][2] It contains meropenem, a β-lactam antibiotic, and vaborbactam, a β-lactamase inhibitor.[1] It is given by injection into a vein.[1]
Combination of | |
---|---|
Meropenem | β-lactam antibiotic |
Vaborbactam | β-lactamase inhibitor |
Clinical data | |
Trade names | Vabomere, Vaborem, others |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
KEGG |
Common side effects include headache, inflammation at the site of injection, nausea, diarrhea, liver inflammation, and low blood potassium.[1] Severe side effects may include anaphylaxis, seizures, and Clostridium difficile-associated diarrhea.[1] It is unclear if use during pregnancy is safe.[3] Meropenem works by blocking the construction of the bacterial cell wall while vaborbactam blocks the breakdown of meropenem by some β-lactamases.[1]
The combination was approved for medical use in the United States in 2017 and Europe in 2018.[1][2] It is on the World Health Organization's List of Essential Medicines.[4]